CLINICAL EFFECT OF A CHINESE HERBAL THERAPY IN HUMAN ASTHMA-PHASE II, PROJECT 2

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 9/16/2008 假设： 这种植物药Ashmi将成为治疗哮喘的有效药物，副作用比目前使用的吸入性皮质类固醇(ICSS)等药物要少。 哮喘是世界范围内的一个主要公共卫生问题，特别是在西方化的社会中，在过去20年中，哮喘的患病率持续上升。ICSS已成为持续性哮喘的一线治疗方法，尽管已有显著副作用的报道。新的哮喘药物，包括白三烯抑制剂和抗IgE，只显示出微乎其微的好处。患者越来越多地转向补充和替代医学(CAM)来治疗他们的哮喘，尽管由于缺乏良好控制的科学研究，其益处尚不确定。我们开发了一种由3种草药组成的中草药配方，称为阿什米(抗哮喘草药干预)。中国先前对91名中重度持续性哮喘患者的研究表明，口服阿司米显著改善肺功能，降低症状评分。最重要的是，没有观察到严重的副作用。 我们最近在西奈山完成了一项第一阶段研究，表明Ashmi具有良好的耐受性，没有明显的副作用。基于这些初步研究，我们假设Ashmi在改善持续中重度哮喘特应性患者的哮喘预后方面将是安全和有效的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 9/16/2008 Hypothesis: The botanical drug, ASHMI, will be an effective treatment for asthma with fewer side effects that currently used drugs such as inhaled corticosteroids (ICSs). Asthma is a major public health problem worldwide, particularly in westernized societies and has continued to increase in prevalence over the past two decades. ICSs have become the first-line treatment for persistent asthma even though significant side effects have been reported. New asthma medications, including leukotriene inhibitors and anti-IgE, have shown only marginal benefits. Patients have increasingly turned to complementary and alternative medicine (CAM) for treatment of their asthma, despite the uncertainty of its benefits due a lack of well-controlled scientific studies. We have developed a Chinese herbal formula composed of 3 herbs called ASHMI (anti-asthma herbal medicine intervention). A previous study in China of 91 moderate-severe persistent asthmatics showed that oral ASHMI significantly improved lung function and reduced symptom scores. Most importantly, no severe side effects were observed. We recently completed a Phase I study at Mount Sinai that showed that ASHMI has good tolerability without significant side effects. Based on these preliminary studies, we hypothesize that ASHMI will be safe and effective in improving the outcome of asthma in atopic patients with persistent moderate-severe asthma.